Oxaliplatin Plus Dual Inhibition of Thymidilate Synthase During Preoperative Pelvic Radiotherapy for Locally Advanced Rectal Carcinoma: Long-Term Outcome

Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer

“…It is reproducible and several scales have been described to better score the relationship between residual tumor and fibrosis induced by radiation treatment. In our experience TRG is suitable to verify the effectiveness of neoadjuvant therapy in rectal tumors [23]. Moreover TRG can help to define possible adjuvant strategies in patients treated into a neoadjuvant setting.…”

Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC

“…Exclusion criteria were: inability to give informed consent, previous rectal surgery, and contraindications to MRI or to MR contrast media. All patients were enrolled within the phase I-II prospective trial described in Avallone et al [19], which was approved by the Independent Ethics Committee of our institution. All patients provided written informed consent to participate in the trial.…”

“…Two different regimens were carried out for the concomitant chemotherapy. Fifty-four patients received bi-weekly bevacizumab at 5 mg/kg plus three bi-weekly cycles of oxaliplatin at 100 mg/m 2 and raltitrexed at 2.5 mg/m 2 on day 1, and levo-folinic acid at 250 mg/m 2 , and 5-fluorouracil at 800 mg/m 2 on day 2 [2,19]. The 20 remaining subjects received capecitabine at a dose of 825 mg/m 2 twice a day, 5 days a week, for 5 weeks.…”

A perspective on the current treatment strategies for locally advanced rectal cancer

“…Notably, few studies have evaluated oxaliplatin and irinotecan at full systemic doses during RT because of potential overlapping toxicities. Interestingly, when full doses of these agents were used, encouraging results have been reported in terms of both pCR and long-term outcomes (Avallone et al, 2011(Avallone et al, , 2012b.…”